La información contenida en este sitio está destinada únicamente a profesionales de la salud en Cuba. Haga clic en "Acepto" si es un profesional de la salud cubano.
Continua expandiendo tu conocimiento y complementando tu practica medica diaria.
Actualiza tu navegador a un version mas reciente o intenta usando las siguientes opciones para navegar de forma eficiente y segura.
Agrega un acceso directo a Diálogo Roche
Agrega un acceso directo a Diálogo Roche: presiona y luego agrégalo a tu pantalla de inicio.
El Congreso nace como una iniciativa académica en conjunto con el Oncólogo Torácico Oscar Arrieta y el Dr. Felipe Couñago realizando una sinergia entre el conocimiento generado en la comunidad científica alrededor del mundo durante el período comprendido entre enero y diciembre de 2021.
Esta fue una actividad organizada en 3 días (26, 27 y 28 de enero de 2022), donde se presentaron médicos de Colombia, Argentina, Costa Rica, Chile, México, Uruguay, Guatemala, Perú y España.
Avalado por: Sociedad Mexicana de Oncología y Sociedad Española de Oncología Radioterápica
Dirigido a: Médicos oncólogos, radio-oncólogos y cirujanos torácicos
Objetivos: Ser una plataforma multidisciplinaria dirigido a médicos jóvenes residentes de las áreas de oncología médica, radiooncología y cirugía torácica, donde médicos especialistas de Iberoamérica puedan exponer y generar un diálogo por medio de foros y mesas de discusión de las mejores investigaciones presentadas en el año 2021.
Puntos de certificación:
No se encontraron resultados para tu búsqueda
Dr. Oscar Arrieta, MX
Dr. Felipe Couñago, ES
Coordinador: Dr. Francisco Corona, MX
-A Prospective Randomized Comparative Study of Three Guided Bronchoscopic Approaches for Investigating Pulmonary Nodules: The PRECISION-1 Study (Chest 2020; 157 (3): 694-701, doi: 10.1016/j.chest.2019.10.016). -Video-assisted thoracoscopic versus open lobectomy in patients with early- stage lung cancer: One-year results from a randomized controlled trial (VIOLET). ASCO 2021, https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8504
Ponente: Dr. Enrique Guzmán de Alba, MX
-Perioperative Outcome of Robotic Approach versus Manual Videothoracoscopic Major Resection in Patients Affected by Early Lung Cancer: Results of a Randomized Study (ROMAN Study). Front Oncol. 2021; 11: 726408. doi: 10.3389/fonc.2021.726408. -Robot-assisted thoracoscopic surgery versus thoracotomy for c-N2 stage NSCLC: short-term outcomes of a randomized trial. Transl Lung Cancer Res. 2019 Dec; 8(6): 951–958, doi: 10.21037/tlcr.2019.11.31
Ponente: Dr. Francisco Javier Moradiellos Díez, ES
-Uniportal Versus Multiportal Video-Assisted Thoracoscopic Lobectomy for Lung Cancer: An Updated Meta-analysis. Lung 2021 Feb;199(1):43-53. doi: 10.1007/s00408-020-00411-9. -Uniportal versus multiportal video-assisted thoracoscopic anatomical resection for NSCLC: a meta-analysis. J Cardiothorac Surg 15, 238 (2020). https://doi.org/10.1186/s13019-020-01280-2
Ponente: Dr. Diego González Rivas, ES
Ponente: Rami Porta, ES
Todos
Coordinador: Dr. Ludwing Alexander Bacon Fonseca, GT
-Update IMpower010: Results of a Phase 3 Study of Atezolizumab vs Best Supportive Care After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (BNSCLC). ASCO 2021, https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_-suppl.8500 - IMpower010: Sites of relapse and subse-quent therapy from a phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in resected stage IB-IIIA NSCLC. ESMO Congress 2021. Abstract LBA9. -Revisión adyuvancia en pacientes con CPCNP no mutados: inmunoterapia.
Ponente: Manuel Cobo, ES
Todos
Coordinador: Dr. Carlos Aliaga Macha, PE
-Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic. Cells 2021 Jul 28;10(8):1912. doi: 10.3390/cells10081912. -Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol 2021 Oct;16(10):1647-1662. doi: 10.1016/j.jtho.2021.06.017. - Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021. Crit Rev Oncol Hematol 2021 May;161:103311. doi: 10.1016/j.critrevonc.2021.103311. - Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer. Front Oncol 2020 Dec 16;10:593831. doi: 10.3389/- fonc.2020.593831. - Liquid biopsy for early stage lung cancer moves ever closer. Nat Rev Clin Oncol 2020 Sep;17(9):523-524. doi: 10.1038/s41571-020-0393-z. - Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study. Clin Lung Cancer 2020 Sep;21(5):e464-e473. - Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. Clin Lung Cancer 2020 Jan;21(1):e10-e14. doi: 10.1016/j.cllc.2019.09.007
Ponente: Dr. Christian Rolfo, EU
Todos
Coordinador: Dr. Victor Manuel Oyervides Juárez, MX
-Update ADAURA: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer. N Engl J Med. 2020;383(18):1711-1723, doi:10.1056/NEJMoa2027071 -Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respiratory Medicine 2021; 9 (9): 1021-29. https://doi.org/10.1016/S2213-2600(21)00134-X -IMPACT: Adjuvant gefitinib versus cisplatin/vinorelbine with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial. J Clin Oncol 2021 Nov 2;JCO2101729. doi: 10.1200/JCO.21.01729. -Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol 2021 Mar 1;39(7):713-722. doi: 10.1200/JCO.20.01820. -Revisión adyuvancia en pacientes con CPCNP mutados
Ponente: Dr. Manuel Dómine Gómez, ES
Todos
Todos
50 min.
Coordinador: Diego Kaen, ES
-Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: LCMC3 Trial Primary Analysis. 2020 WCLC, Abstract PS02.05. https://doi.org/10.1016/j.jtho.2021.01.320 -CheckMate 816: Neoadjuvant Nivolumab + Platinum Chemotherapy for Resectable Stage IB-IIIA NSCLC. ASCO 2021. J Clin Oncol. 2021;39(suppl 15):8503-8503). doi:10.1200/JCO.2021.39.15_suppl.8503 and AACR 2021 Cancer Res 2021;81(13_Suppl):Abstract nr CT003. -Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. The Lancet Oncology 2021; 22 (6): 824-835. https://doi.org/10.1016/S1470-2045(21)00149-2 -Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020 Nov;21(11):1413-1422. - NADIM: Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer
Ponente: Dr. Oscar Gerardo Arrieta Rodríguez, MX
(NSCLC): A Phase II Multicenter Exploratory Study. Pre-treatment Levels of ctDNA May Be Useful in Future Clinical Trials to Predict Long-Term Survival. 2021 WCLC Abstract OA20.02 and Lancet Oncol 21:1413-1422, 2020. -Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. - Pathological Response is an Independent Factor of Overall Survival and Disease-free Survival After Neoadjuvant Durvalumab in Resectable Nonsmall Cell Lung Cancer (NSCLC) in the IFCT-1601 IONESCO Phase Il Trial. ESMO Meeting 2021 Annals of Oncology (2021) 32 (suppl_5): S931-S938. 10.1016/annonc/annonc727 -SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J Clin Oncol 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. -Neoadjuvant immune checkpoint inhibitors in resectable non-small cell lung cancer: a systematic review. ESMO Open 2021 Oct;6(5):100244. doi: 10.1016/j.esmoop.2021.100244. - Revisiting neoadjuvant therapy in non-small cell lung cancer. The Lancet Oncology 2021; 22 (11): 501-516. https://- doi.org/10.1016/S1470-2045(21)00383-1
Ponente: Dr. Oscar Gerardo Arrieta Rodríguez, MX
- A phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutant non-small cell lung cancer: updated results. Presented at: 2021 World Conference on Lung Cancer. Abstract P26.02. -EMERGING: A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of GC as (Neo)Adjuvant Treatment in Stage IIIA-N2 NSCLC With Sensitizing EGFR Mutation in Exon 19 or 21. ASCO 2021, https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8502 - Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer. Transl Lung Cancer Res. 2021 Jan;10(1):607-621. doi: 10.21037/tlcr-20-780. - Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials. Front Oncol. 2021 Jan 12;10:586596. doi: 10.3389/- fonc.2020.586596.
Dr. Gonzalo Recondo, AR
Todos
30 min.
Coordinador: Dra. Mónika Blake Cerda, MX
-An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART. Lancet Oncol 2021 Dec
Ponente: Dr. Javier Serrano, MX
14;S1470-2045(21)00606-9. doi: 10.1016/S1470-2045(21)00606-9. -Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy. The Phase 3 PORT-C Randomized Clinical Trial. JAMA Oncol 2021 Aug 1;7(8):1178-1185. doi: 10.1001/jamaoncol.2021.1910. -Revisión evidencia Radioterapia adyuvante
Ponente: Dr. Javier Serrano, MX
Todos
30 min.
Coordinador: Dra. Dolores de la Mata, MX
-PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC. ASCO 2021. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8511 -Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6). European Lung Cancer Congress 2021. Journal of Thoracic Oncology (2021) 16 (suppl_4): S737-S747 -PACIFIC-R: real-world characteristics of unresectable Stage III NSCLC patients treated with durvalumab after chemoradiotherapy. European Lung Cancer Congress 2021. Journal of Thoracic Oncology (2021) 16 (suppl_4): S737-S747.
Ponente: Dr. David Vicente Baz, ES
- S-REAL: Características de los pacientes con CPNM estadio III irresecable tratados con Durvalumab tras Quimiorradioterapia dentro del Programa de Medicamentos de Uso Especial en España PACIFIC. SEOM 2021 O-22.
Ponente: Dr. David Vicente Baz, ES
Todos
30 min.
Coordinador: Dr. Luis Mas Pérez, PE
-Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. -A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST). ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741 -The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. J Thorac Oncol 2021 Aug;16(8):1392-1402. doi: 10.1016/j.jtho.2021.04.019.
Ponente: Dr. Claudio Martín, AR
-Real-World Treatment Patterns and Clinical Outcomes in Patients with Stage III NSCLC: Results of KINDLE, a multicountry observational study. J Thorac Oncol 2021; 16 (10): 1733-1744. -Revisión inmunoterapia en enfermedad localmente avanzado en CPCPNP: más allá del PACIFIC
Ponente: Dr. Claudio Martín, AR
Todos
Dr. Felipe Couñago Lorenzo, ES
Dr. Oscar Arrieta Rodríguez, MX
30 min.
Dra. Marisol Arroyo Hernández, MX
The TALENT Study. Abstract PS01.02. Presented at World Conference on Lung Cancer Virtual Conference, 2020 J Thorac Oncol. 2021;16(3):S58. -Defining High Risk. Abstract ES 12.02. WCLC 2020. https://www.jto.org/action/showPdf?pii=S15560864%2821%2900073-3 - Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. The LANCET Regional Health 2021; 10: 100179. https://doi.org/10.1016/j.lanepe.2021.100179. -Comparing U.S. Preventive Services Task Force 2013 versus 2021 lung cancer screening eligibility. ASCO 2021 Abstract 13. https://meetinglibrary.asco.org/record/201698/abstract -USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2021 Dec 10:S1470-2045(21)00590-8. doi: 10.1016/S1470-2045(21)00590-8. -Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA. 2021 Mar 9;325(10):988-997. doi:
Dra. Lucía Viola Muñoz, CO
10.1001/jama.2021.1077. -Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. J Clin Oncol 2021 Aug 10;39(23):2574-2585. doi: 10.1200/JCO.20.02574. -Low-Dose Chest Computed Tomographic Screening and Invasive Diagnosis of Pulmonary Nodules for Lung Cancer in Never-Smokers. WCLC 2020. Abstract MA05.05. https://www.jto.org/action/showPdf?pii=S1556-0864%2821%2900211-2 -Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST. WCLC 2020 Abstract MA05.08. https://www.jto.org/action/showPdf?pii=S15560864%2821%2900211-2 -Mobile low-dose computerized tomography (LDCT): Three-year follow up of solution for early diagnosis of lung cancer in under-served populations. ASCO 2021 Abstract 6507. https://meetinglibrary.asco.org/record/201551/abstract -Differences in Detection Patterns, Characteristics, and Outcomes of Central and Peripheral Lung Cancers in Low-Dose CT Screening. WCLC 2021 Abstract OA19.03. -Lung Cancer Detected By Screening, Incidental Lung Nodule Program and Neither: A Prospective Observational Study. WCLC 2021 Abstract MA10.02 - Balance Between Decreased False Positives and Delayed Diagnosis in Lung Cancer Screening. WCLC 2021 Abstract MA10.03 - Reflections on the Implementation of Low-dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain. 2021 DOI: 10.1016/j.arbr.2017.08.006
Dra. Lucía Viola Muñoz, CO
Todos
30 min.
Coordinador: Dr. Felipe Couñago Lorenzo, ES
-Predictors of Pneumonitis After Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer. Int J Radiat Oncol Biol Phys 2021 Dec 1;111(5):1176-1185. doi: 10.1016/j.ijrobp.2021.07.1691. -Highlights ASTRO 2021: -Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. JAMA Oncol 2021 Oct 1;7(10):1497-1505. doi: 10.1001/jamaoncol.2021.3186. -A phase 2 trial of primary tumor SBRT Boost prior to concurrent chemoradiation for locally-Advanced Non-Small Cell Lung Cancer (LA NSCLC). Int J Radiat Oncol, Biol Phys 2021; 111 (3) S1: S90. -Cardiac Radiation Dose and Patients Risk Factors for predicting major adverse cardiac events in lung cancer patients. ASTRO 2021
Ponente: Dr. Federico Maldonado Magos, MX
Todos
50 min.
Coordinador: Dr. Jerónimo Rafael Rodríguez Cid, MX
-First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. -First-line nivolumab plus ipilimumab in advanced non-small cell lung cancer: 4-year outcomes from the randomized open-label, Phase 3, Checkmate 227. ASCO 2021. J Thorac Oncol 2021 Oct 12;S1556-0864(21)03207-X. -Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2021 Sep;32(9):1137-1147. -IMpower 150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups with EGFR Mutations or Metastases in the Liver or the Brain. J Thorac Oncol 2021. https://doi.org/10.1016/j.jtho.2021.09.014 -Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KN 021, 189 and 407. J Thorac Oncol 2021 Nov;16(11):1883-1892. doi: 10.1016/j.jtho.2021.06.020.
Ponente: Dr. Luis Paz-Ares, ES
-Atezolizumab vs Platinum-based Chemo in Blood-based Tumour Mutational Burden-positive (bTMB+) Patients with First-line (1L) Advanced/metastatic (m) NSCLC: Results of the Blood First Assay Screening Trial (BFAST) Phase Ill Cohort C. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 - EMPOWER-Lung 3: Cemiplimab in Combination with Platinum Doublet Chemotherapy for First Line (1L) Treatment of Advance Non-Small Cell Lung Cancer (NSCLC). ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741 -Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. J Clin Oncol 2021 Jul 20;39(21):2327-2338. doi: 10.1200/JCO.20.03579. -Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JAMA Oncol 2021 Jun 1;7(6):937-939. doi: 10.1001/jamaoncol.2021.0546.
Ponente: Dr. Luis E. Raez, EU
Todos
40 min.
Coordinador: Dr. Osvaldo Aren, UY
Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer. Clin Cancer Res 2021 Oct 22. doi: 10.1158/1078-0432.CCR-21-2649. -Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol 2021 Dec;32(12):1597-1607. doi: 10.1016/j.annonc.2021.08.2151. -Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol 2021 Nov;32(11):1391-1399. doi: 10.1016/j.annonc.2021.08.1744. -IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. Ann Oncol 2021 Jun;32(6):736-745. doi: 10.1016/j.annonc.2021.02.016. -Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res 2021 Sep 15;27(18):5131-5140. doi: 10.1158/1078-0432.CCR-21-0921 - Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2021 Dec;22(12):1740-1751. doi: 10.1016/S1470-2045(21)00584-2
Ponente: Dra. Carmen Pupareli, AR
-Activity of OSE-2101 in HLA-A2+ Non-Small Cell Lung Cancer Patients After Failure to Immune Checkpoint Inhibitors (IO): Final Results of Phase III Atalante -1 Randomized Trial. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741 -Cityscape: Updated Analysis and Patient-Reported Outcomes (PROs) from of CITYSCAPE: A Randomized, Double-Blind, Phase II Study of the anti-TIGIT Antibody Tiragolumab + Atezolizumab (TA) Versus Placebo + Atezo (PA) as First-Line Treatment For PD-L1+ NSCLC. ESMO Immuno-Oncology 2021 Abstract LBA2 -First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Ann Oncol 2021 Nov 18;S0923-7534(21)04776-1. doi: 10.1016/j.annonc.2021.11.002. - Atezo Brain: non-randomized phase II clinical trial of atezolizumab combined with carboplatin plus pemetrexed in chemotherapy naïve patients with advanced non-squamous NSCLC with untreated brain metastases. 2021 WCLC. Abstract OA09.02 https://doi.org/10.1016/j.jtho.2021.08.062
Ponente: Dr. Delvys Rodríguez, ES
Todos
50 min.
Coordinador: Dr. Mauricio Cuello, CL
- Bevacizumab + Erlotinib vs Erlotinib Alone as First-Line Treatment of Patients with EGFR Mutated Advanced Non-Squamous NSCLC: Final Analysis of the Multicenter, Randomized, Phase IlI BEVERLY Trial. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 - Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med 2021 Aug 26;S2213-2600(21)00166-1. -RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 2021 Jul 22. doi: 10.1158/1078-0432.CCR-21-0273. - Amivantamab Monotherapy and in Combination with lazertinib in Post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS Study. ESMO 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 -Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. JAMA Oncol 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758. -A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol 2021 Nov 26;S0923-7534(21)04825-0. doi: 10.1016/j.annonc.2021.11.010.
Ponente: Dr. Rafael Rosell
--AENEAS: Phase III Trial of First-line Aumolertinib vs Gefitinib in Advanced EGFR-Mutated NSCLC. ASCO 2021. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.9013 -Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov 2021 Sep 21; candisc.0715.2021. -ORCHARD Osimertinib + Savolitinib Interim Analysis: A Biomarker-Directed Phase II Plataform Study in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Disease has Progressed on First-Line (1L) Osimertinib. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 - Phase 1b Study of Pelcitoclax (APG-1252) in Combination with Osimertinib in Patients with EGFR TKI-resistant NSCLC. 2021 WLCL https://doi.org/10.1016/j.jtho.2021.08.115 -A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clin Cancer Res 2021 Dec 17;clincanres.3194.2021. doi: 10.1158/1078-0432.CCR-21-3194. -Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). Clin Cancer Res 2021 Feb 1;27(3):704-712. doi: 10.1158/1078-0432.CCR-20-3063.
Dr. Luis Lara Mejía, MX
- Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study. ESMO 2021 Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741
Dr. Luis Lara Mejía, MX
Todos
Todos
30 min.
Coordinador: Dra. Pamela Soberanis, MX
-Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol 2021 Dec 1;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761. - Mobocertinib in EGFR Exon 20 Insertion-positive Metastatic NSCLC Patients with Disease Control on Prior EGFR TKI Therapy. WCLC 2021. https://doi.org/10.1016/j.jtho.2021.08.082 - Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.01.284
Dr. Jordi Remón, ES
- High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from a phase 2 multicenter study, POSITION20. ESMO Meeting 2021. Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729 - Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.297 - Phase 1 Studies of DZD9008. an Oral, Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon 20 Insertion Mutation. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.083
Dr. Jordi Remón, ES
Todos
30 min.
Dr. Suraj Samtani, CL
-Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res 2021 Nov 17. doi: 10.1158/1078-0432.CCR-21-2733. - Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients with previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.085 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS. 2021 WCLC http://dx.doi.org/10.1016/j.jtho.2021.08.084
Ponente: Dra. Rosario García Campelo, ES
-Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med 2021 Oct;9(10):1154-1164. doi: 10.1016/S2213-2600(21)00084-9. - Real World Next-Generation Sequencing and Treatment Patterns in Non-Small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations. ESMO Meeting 2021 Abstract 1259P -MET-driven acquired resistance in fusion-positive NSCLC. 2021 WCLC. https://doi.org/10.1016/j.jtho.2021.08.113
Ponente: Dra. Rosario García Campelo, ES
Todos
30 min.
Coordinador: Dr. Luis Cabrera Miranda, MX
-Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. - Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med 2021 Sep 18. doi: 10.1056/NEJMoa2112431. - Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol 2021 Nov 29;JCO2101323. doi: 10.1200/JCO.21.01323.
Ponente: Dr. Bartomeu Masutti, ES
-Efficacy of ICI Alone or in Combination with Chemotherapy in NSCLC harboring ERBB2 Mutations. J Thorac Oncol 2021 Nov;16(11):1952-1958. doi: 10.1016/j.jtho.2021.06.025. -Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021 Jul;22(7):959-969. doi: 10.1016/S1470-2045(21)00247-3. -Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. Clin Cancer Res 2021 Aug 1;27(15):4160-4167. doi: 10.1158/1078-0432.CCR-21-0800.
Ponente: Dr. Bartomeu Masutti, ES
-Acquired Resistance to KRAS G12C Inhibition in Cancer. N Engl J Med 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281. -Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. -Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. J Clin Oncol 2021 Sep 1;39(25):2791-2802. doi: 10.1200/JCO.20.03307. -Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer. Lung Cancer 2021 Jan;151:53-59. doi: 10.1016/j.lungcan.2020.11.023. -NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. Clin Cancer Res 2021 Feb 1;27(3):877-888. doi: 10.1158/1078-0432.CCR-20-1985
Ponente: Dra. Ivana Sullivan, ES
- TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors. WCLC 2021. DOI: https://doi.org/10.1016/j.jtho.2021.08.118
Ponente: Dra. Ivana Sullivan, ES
Todos
30 min.
Coordinador: Dr. Mauricio Burotto, CL
-Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol 2021 Nov 1;7(11):1617-1625. doi: 10.1001/jamaoncol.2021.3523. -Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 2021 May;32(5):620-630. doi: 10.1016/j.annonc.2021.02.012. - Pembrolizumab in Combination with Platinum-based Chemotherapy in Recurrent EGFR/ALK+ Non-Small Cell Lung Cancer (NSCLC). 2021 WCLC Abstract OA09.03 https://doi.org/10.1016/j.jtho.2021.08.063 - Co-occurring CDKN2A/B alteration is associated with worse survival outcomes in advanced ALK-positive non-small cell lung cancer. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.479
Ponente: Javier De Castro, ES
- B-FAST: Blood First Assay Screening Trial (BFAST) in Treatment-Naïve Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. J Thorac Oncol 2021 Dec;16(12):2040-2050. doi: 10.1016/j.jtho.2021.07.008. -Editorial: Optimized Alectinib Dose Regimen for Treatment for Patients with ALK-Positive NSCLC Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence. Clin. Pharmacol. Ther.110, 1164 (2021). https://doi.org/10.1002/cpt.2372.
Ponente: Javier De Castro, ES
Todos
Dr. Oscar Arrieta Rodríguez, MX
Dr. Felipe Couñago Lorenzo, ES
30 min.
Coordinador: Dr. Ernest Nadal, ES
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet Respiratory Medicine 2021; 9 (5): P467-75. https://doi.org/10.1016/S2213-2600(20)30391-X -Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2021 Jan 1;7(1):92-106. doi: 10.1001/jamaoncol.2020.6146. -Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II). JAMA Oncol 2021 Oct 1;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. -Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol 2021 Jul;22(7):1023-1033. doi: 10.1016/S1470-2045(21)00196-0. -Highlights ASTRO 2021:
Ponente: Dr. Javier Luna, ES
- A randomised phase 2 trial of nivolumab and SBRT in advanced NSCLC, progressing after first or second-line chemotherapy (NIVORAD). -Stereotactic body radiotherapy with biologically equivalent dose >150Gy is associated with improved local control in patients with squamous but not non-squamous cell carcinoma of the lung: a multi-institutional analysis. -Targeted high-dose radiation therapy led to a fivefold improvement in progression-free survival for patients with oligoprogressive lung cancer. -The potential for individualized SABR dosing to treat lung tumours.
Ponente: Dr. Javier Luna, ES
Todos
30 min.
Coordinador: Dr. Francisco Lozano Ruíz, MX
-Mature outcomes of 61,2 Gy Concomitant Boost Thoracic Radiotherapy in Limited Stage small cell lung cancer LSSCLC: CALGB 30610 Alliance/RTOG 0538. ASCO 2021 https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8505 -Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). ASCO 2021 https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.9007
Ponente: Dra. Nuria Rodríguez de Dios, ES
-Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study. J Thorac Oncol 2021 May;16(5):840-849. doi: 10.1016/j.jtho.2020.12.024. -Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol 2022 Jan;33(1):67-79. doi: 10.1016/j.annonc.2021.09.011
Ponente: Dra. Nuria Rodríguez de Dios, ES
Todos
30 min.
Coordinador: Dr. David Heredia
- Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. - IMpower133: exploratory analysis of maintenance therapy in patients with ES-SCLC. 2020 WCLC. - Impower133: gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo). ESMO Meeting 2021.
Ponente: Dr. Santiago Ponce Aix , ES
-Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. J Clin Oncol 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212. -Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol 2021 May;32(5):631-641. doi: 10.1016/j.annonc.2021.01.071.
Ponente: Dr. Santiago Ponce Aix, ES
Todos
Todos
30 min.
Coordinador: Dra. Laura Bolaño, MX
-Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol 2021 Feb;22(2):190-197. doi: 10.1016/S1470-2045(20)30606-9. -First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. -Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: Preliminary results from the CONFIRM phase 3 trial. The Lancet Oncology 2021; 22 (11): 1530-40. https://doi.org/10.1016/S1470-2045(21)00471-X
Ponente: Dra. Dolores Isla, ES
-A Randomized Phase II trial of Oral Vinorelbine as Second-Line Therapy for Patients with Malignant Pleural Mesothelioma. ASCO 2021. https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.8507 -Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2021 Oct;22(10):1438-1447. -Pembrolizumab and Nintedanib for Patients with Advanced Mesothelioma. ESMO Meeting 2021 Annals of Oncology (2021) 32 (suppl_5): S1199-S1204. 10.1016/annonc/annonc730 -A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov 2021 Nov;11(11):2748-2763. doi: 10.1158/2159-8290.CD-21-0407.
Ponente: Dra. Dolores Isla, ES
Todos
30 min.
Coordinador: Dra. Renata Baez, MX
- Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer 2021 Jul; 157: 109-115. doi: 10.1016/j.lungcan.2021.05.014. - Effect of COVID-19 on Thoracic Oncology Surgery in Spain: A Spanish Thoracic Surgery Society (SECT) Survey. Cancers (Basel) 2021 Jun 9;13(12):2897. doi: 10.3390/cancers13122897.
Ponente: Dr. Luis Corrales, CR
- Depression, anxiety and distress impact in patients with thoracic malignancies during the COVID-19 pandemic. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.092 - Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies. Oncologist 2021 Dec;26(12):1035-1043. doi: 10.1002/onco.13962. - Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19. Lancet Respir Med. 2021 Aug;9(8):e78-e79. doi: 10.1016/S2213-2600(21)00240-X. - Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer 2021 Oct;160:78-83. doi: 10.1016/j.lungcan.2021.07.002.
Ponente: Dr. Luis Corrales, CR
Todos
20 min.
Coordinador: Dr. Edgar Varela, MX
-Efficacy and Safety of Nivolumab for Patients with Pre-treated Type B3 Thymoma and Thymic Carcinoma: Results from the EORTC-ETOP NIVOTHYM Phase Il Trial. 2021 WCLC https://doi.org/10.1016/j.annonc.2021.08.2147 -Revisión tratamiento neoplasias timo: evidencia hasta el momento.
Ponente: Dr. Leonardo Rojas, CO
Todos
90 min
Coordinadores: Dr. Oscar Arrieta, MX Dr. Felipe Couñago, ES
-Estudios españoles 2021 Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study. Transl Lung Res 2021 Oct;10(10):3902-3911. doi: 10.21037/tlcr-21-559. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. ESmo Open 2021 Oct;6(5):100279. doi: 10.1016/j.esmoop.2021.100279. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. BMC Cancer 2021 Aug 31;21(1):977. doi: 10.1186/s12885-021-08713-8. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. J Immunother Cancer 2021 Aug;9(8):e002804. doi: 10.1136/- jitc-2021-002804.
Ponente: Dr. Mariano Provencio, ES
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant chemoimmunotherapy Clin Cancer Res 2021 Nov 1;27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200. Epub 2021 Aug 10. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clin Transl Med 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. Plos One 2021 Jun 2;16(6):e0251761. doi: 10.1371/journal.pone.0251761. Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations Transl Lung Cancer Res 2021 2021 Apr;10(4):1761-1772. doi: 10.21037/tlcr-20-1055. Residential radon and lung cancer characteristics at diagnosis. Int j radiat biol 2021;97(7):997-1002. doi: 10.1080/09553002.2021.1913527. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. BMC Cáncer 2021 Mar 6;21(1):230. doi: 10.1186/s12885-021-07922-5. Small-cell lung cancer in never-smokers. ESMO open 2021 Apr;6(2):100059. doi: 10.1016/j.esmoop.2021.100059.
Ponente: Dr. Mariano Provencio, ES
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Lung Cancer 2021 Mar; 153:25-34. doi: 10.1016/j.lungcan.2021.01.005.
Ponente: Dr. Mariano Provencio, ES
-Estudios latinoamericanos 2021 -Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. Cancer Discov 2021 Mar;11(3):591-598. doi: 10.1158/2159-8290.CD-20-1165. - A high number of co-current genetic alterations is associated with poor survival in EGFR mutated metastatic NSCLC patients. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.620 - Body mass index predicts benefit from adding metformin to EGFR-TKIs in patients with lung cancer adenocarcinoma: sub analysis from an RCT. 2021 WCLC https://doi.org/10.1016/j.jtho.2021.08.520 p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. Transl Oncol 2022 Jan;15(1):101276. doi: 10.1016/j.- tranon.2021.101276. -Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma. Front Oncol 2021 Apr 20;11:641975. doi: 10.3389/fonc.2021.641975.
Ponente: Dr. Andrés Cardona, CO
-RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. BMC Cancer 2021 Aug 5;21(1):892. doi: 10.1186/s12885-021-08287-5. -Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer 2021 Nov;22(6):510-522. doi: 10.1016/j.cllc.2021.03.014. Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized phase 2 Study (PRoT-BM trial). Int J Radiat Oncol Biol Phys 2021 Aug 1;110(5):1442-1450. -Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. Lung Cancer 2021 May;155:183-190. doi: 10.1016/j.lungcan.2021.01.023. -The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival. Nutr Cancer 2021;73(5):794-801. doi: 10.1080/01635581.2020.1769691. -Failure to EGFR-TKI-based therapy and tumoral progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. Eur J Cancer 2022 Jan;160:189-205. doi: 10.1016/j.ejca.2021.10.032. -Prophylactic Cranial Irradiation in Patients With High-Risk Metastatic Non-Small Cell Lung Cancer: Quality of Life and Neurocognitive Analysis of a Randomized Phase II Study. Int J Radiat Oncol Biol Phys 2021 Sep 1;111(1):81-92.
Ponente: Dr. Andrés Cardona, CO
-Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America. Mol Clin Oncol 2022 Jan;16(1):6. doi: 10.3892/mco.2021.2439.
Ponente: Dr. Andrés Cardona, CO
Todos
Coordinadores: Dr. Oscar Arrieta, MX Dr. Felipe Couñago, ES
El presente material puede contener información referida a medicamentos bajo investigación o en indicaciones aún no aprobadas, con el único objetivo de utilización reactiva a consultas recibidas por profesionales de la salud a fin de brindar información médica y/o científica.
Roche no recomienda el uso de ningún producto en cualquier indicación, dosis o vía de administración que no esté claramente mencionado en la información para prescribir del producto aprobado por la autoridad regulatoria local.
Los puntos de vista y opiniones expresadas en este material son exclusiva responsabilidad de los autores y no representan necesariamente las opiniones de Roche.
Accederás a contenido complementario que podría no ser propiedad de Roche. De ser así, Roche no asume responsabilidad por el acceso, uso y contenidos de este sitio web.
Si deseas quedarte en Diálogo Roche da clic en "Regresar".
Lo sentimos, tu lista de favoritos solo puede guardar hasta 100 contenidos. Puedes hacer espacio borrando contenidos que ya no sean de tu interés e intentarlo nuevamente.
M-CR-00000876